Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
March 12, 2019 16:05 ET
|
Clearside Biomedical, Inc.
- Novel Retinal Treatment Demonstrates Potential of Proprietary Therapeutic Platform -- XIPERE™ NDA Accepted and On Track for October 19, 2019 PDUFA Date -- Management to Host Webcast and Conference...
Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference
March 04, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 04, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical to Report 2018 Financial Results and Provide Corporate Update on Tuesday, March 12, 2019
February 27, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019
February 20, 2019 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical’s Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society
February 19, 2019 07:05 ET
|
Clearside Biomedical, Inc.
- Presentations highlighted data analyses across multiple disease states - - New, nonclinical data indicates potential for suprachoroidal administration of gene-based therapies - ALPHARETTA, Ga.,...
Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
January 20, 2019 11:15 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 20, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 08:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis
December 19, 2018 16:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 08, 2018 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...
Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference
November 07, 2018 16:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for...